Latest Cancer News

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer (10-23-2014)
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According... Continue Reading

FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC (10-22-2014)
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to an investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (10-21-2014)
The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results... Continue Reading

More Cancer News

Locations

COLCHESTER
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
792 College Parkway, Suite 207
Colchester, Vermont   05446
TEL: (802) 655-3400
FAX: (802) 655-9170

ST ALBANS
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
4 Crest Road,
St. Albans, VT 05478
TEL: (802) 524-0537
FAX: (802) 524-0538

MIDDLEBURY
Vermont Center for Cancer Medicine and Blood Disorders, Inc.
110 Porter Drive,
Middlebury, VT 05753
TEL: (802) 388-8977
FAX: (802) 388-8976